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Material and Methods: A bioanalytical assay based on mass spectrometry
that allows the simultaneous monitoring of gem as well as its active (dFdCTP)
and inactive (dFdU) metabolites was developed in the context of this study.
The balance of gem and its active/inactive metabolites, a crucial indicator
of efficacy, was evaluated in cell lines after treatment with gem or GSG.
Furthermore, since GSG’s structure contains a potent agonist peptide of
the GnRH-R we investigated whether it could have a central effect through
the pituitary by performing testosterone measurements in animals dosed
with GSG. In addition, an in vitro colony forming hematotoxicity assay was
developed in order to compare the hematoxic potential of GSG and gem.
Results and Discussion: GSG appears to offer a metabolic advantage
in comparison to gem which is a beneficial attribute in conditions of gem
acquired resistance. The ratios of dFdCTP/dFdU were significantly higher in
DU145 cells incubated with GSG versus gem. When GSG was administered
acutely in mice, it caused a rapid increase of testosterone concentrations
in 2 h suggesting that GSG is a potent GnRH-R agonist. After continuous
administration of GSG in mice (21 day protocol), testosterone levels dropped
to baseline levels (59±11 vs 1±0.9 ng/mL in plasma and 2010±296 vs
400±197 ng/g in testes). Importantly, in an in vitro hematotoxicity colony
forming assay we demonstrated that GSG was less toxic in comparison to
gem (IC90 of 17.2 vs 6.8 nM).
Conclusion: The findings of our study along with the targeted delivery nature
of the GSG analogue could offer a powerful and unique approach to prostate
cancer treatment: a single nontoxic molecule can be used to reach the
tumour site selectively, improve the distribution and metabolic properties of
the cytotoxic agent (gem), and act as an agonist that ablates testosterone
release following repeated dosing. The multiple modes of action of GSG are
currently being evaluated by our team in appropriate prostate cancer animal
models.
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Introduction: KRAS is mutated in ~80% of pancreatic ductal adenocarcinoma
(PDAC), ~35% of colorectal cancer (CRC) and ~20% of non-small-cell lung
cancer (NSCLC). KRAS remains an intractable drug target and targeting the
downstream pathway component is ineffective because feedback mechanisms
or parallel pathways provide alternative routes to cell proliferation and/or
survival.
Results and Discussion: Here we show that CCT3833, the clinical candidate
from our in house panRAF/SRC inhibitor series, is active in KRASmutant
PDAC, CRC and NSCLC. We demonstrate that CCT3833 inhibits tumor
growth in several KRAS-driven cancers via inhibition of RAF and SRC,
eliciting therapeutic efficacy at well-tolerated doses in mouse models of human
cancer.
Conclusion: CCT3833 has entered clinical trials (NCT02437227) for BRAF
mutant and BRAF inhibitor-resistant melanomas and our data here show
that it is also effective in KRAS mutant cancers, potentially providing a new
therapeutic option for these patients.
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Background: Penile Carcinoma (PeCa) corresponds to a mutilating men’s
malignant tumor. It is more frequent in underprivileged socioeconomic regions
(e.g., N, NE Brazil). Five-year survival rates drops dramatically in patients with
lymph node metastasis. The major risk factors include poor local hygiene,
phimosis, and Human Papilloma Virus (HPV) infection. In the present study,
it was our objective to provide molecular information regarding the differential
protein pattern in PeCa and look for potential diagnostic, prognostic and/or
predictive biomarkers.
Material and Methods: Twenty-four frozen samples were obtained from
patients, fourteen cases of penile squamous cell carcinoma, usual type, and
ten samples of normal control specimens, postectomy (n = 4) and adjacent
normal tissue (n = 6), were submitted to 2D gel-based proteomic. Next, liquid
chromatography coupled with a mass spectrometry was used to reveals the
protein identity of the differential 2D spots from PeCa HPV positive versus
PeCa HPV negative comparison. Furthermore, bioinformatics tools assessed
the protein-protein interactions.
Results: Twenty-nine differentially expressed proteins were identified, 22 of
them were downregulated and seven were upregulated in HPV-associated
PeCa. The interactions network has demonstrated, among others, proteins,
which were overexpressed in PeCa HPV negative samples, related to loss
of cellular adhesion (e.g., moesin) and gain of oxidative stress defense
(e.g., peroxiredoxin-2), that contribute to metastases and cellular survival,
respectively. These results suggest that the absence of HPV infection might
represents a facilitating factor of tumor progression, that could explains the
frequent poorly prognosis associated with HPV negative PeCa.
Conclusions: Our data provide news insights on the characterization of PeCa
and may be useful for the development of biomarkers with significant clinical
value.
No conflict of interest.
864 RNA sequencing reveals a distinct transcriptomic profile
predictive of clinical outcome in stage III colorectal cancer
patients treated with adjuvant chemotherapy
E. Mini1, R. D’Aurizio2, G. Perrone1, A. Magi1, A. Lapucci1, R. Tassi1,
C. Napoli3, L. Picariello4, I. Landini1, S. Nobili3. 1University of Florence,
Department of Experimental and Clinical Medicine, Firenze, Italy, 2National
Research Council CNR, LISM-IIT, Pisa, Italy, 3University of Florence, Health
Sciences, Firenze, Italy, 4University of Florence, Department of Biomedical
Experimental and Clinical Sciences “Mario Serio”, Firenze, Italy
Introduction: 5-year overall survival of stage III colorectal cancer (CRC)
patients (pts) treated with standard adjuvant chemotherapy (CHT) (a
fluoropyrimidine − FP − with/without oxaliplatin − OHP) is still unsatisfactory
and highly variable (42−88%). Although single molecular biomarkers and
molecular signatures predictive of adjuvant CHT outcome have been identified
in CRC, none of them has been validated. We hypothesized that differences in
gene expression may be responsible for the variability of prognosis of stage III
CRC pts. The goal of this study was to identify molecular biomarkers predictive
of response to FP-based adjuvant CHT in stage III CRC pts. MATERIAL
AND Methods: From a large case series of CRC pts who received standard
adjuvant CHT (5-fluorouracil/capecitabine with/without OHP) we selected two
groups with favorable (no evidence of disease recurrence within 5 yrs from
CHT, n = 12) or unfavorable (evidence of disease recurrence within 3 yrs from
CHT, n = 12) prognosis, according to stringent eligibility criteria. We analyzed
fresh frozen primary CRC explants according to an IRB-approved protocol.
Whole transcriptomic sequencing was performed by Ion Proton System (Ion
Torrent Thermo Fisher Scientific). After quality control, produced reads were
aligned to all transcripts to measure the gene expression levels in each sample.
To identify differentially expressed genes between the two groups a statistical
analysis was performed using DESeq2 package of R Bioconductor repository.
Oncomine database was used to classify genes.
Results: Bioinformatic analysis identified 108 differentially expressed genes
between the two groups (p value <0.01, False Discovery Rate <0.01): 104
genes were upregulated and 4 downregulated in the unfavorable prognosis
group compared with the favorable prognosis group. Magnitude of fold changes
was within −2.5 to +3.5. Among these, 42 genes belonging to the olfactory
signaling pathways, were not further considered. Among 66 remaining genes,
19 were pseudogenes, 7 uncharacterized non-coding RNA, 4 were involved
in the immune response (e.g. IFNs) and one was a miRNA (MIR548I1).
All these genes were upregulated. Further 9 genes were cancer-related (6
upregulated (e.g. CETN1 involved in cell adhesion) and 3 downregulated (e.g.
ROR2 involved in Wnt pathway). The remaining genes (n = 26), most of which
involved in key cellular processes (e.g. RNA processing: UPF3A upregulated;
apoptosis: TMEM150B downregulated) have not yet been associated with
cancer and/or cancer prognosis. A validation of differentially expression genes
is ongoing by RT-PCR.
Conclusion: Stage III CRC pts with favorable and unfavorable prognosis
following adjuvant CHT differs at a transcriptomic level. These findings, after
a proper validation in an independent cohort, may have important implications
for FP-based adjuvant CHT.
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